<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02806570</url>
  </required_header>
  <id_info>
    <org_study_id>4433</org_study_id>
    <nct_id>NCT02806570</nct_id>
  </id_info>
  <brief_title>Early Feasibility Study of the AccuCinch® Ventricular Repair System</brief_title>
  <official_title>Early Feasibility Study of the AccuCinch® Ventricular Repair System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ancora Heart, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ancora Heart, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, non-randomized, prospective Early Feasibility Study to evaluate the
      AccuCinch® Ventricular Repair System in patients with symptomatic heart failure and
      concomitant functional mitral regurgitation that have stable symptoms on guideline-directed
      medical therapy
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>30-day</time_frame>
    <description>Device-related or procedure-related major adverse events (MAEs)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Heart Failure</condition>
  <condition>Mitral Valve Insufficiency</condition>
  <condition>Cardiomyopathies</condition>
  <arm_group>
    <arm_group_label>AccuCinch® Ventricular Repair System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mitral valve repair</intervention_name>
    <arm_group_label>AccuCinch® Ventricular Repair System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Study patient is an adult of legal consent age.

          -  Severity of functional mitral regurgitation (FMR): ≥ Moderate (i.e., 2+, according to
             2003 ASE Guidelines for grading mitral regurgitation)

          -  Ejection Fraction: ≥20 to ≤60%

          -  Symptom Status: New York Heart Association (NYHA) II-IVa (i.e., ambulatory)

          -  Treatment and compliance with optimal guideline directed medical therapy for heart
             failure for at least 1 month

          -  Surgical risk: Subject is eligible for cardiac surgery (specific risk score or
             comorbidities should demonstrate high risk features, as determined by the Heart Team)

          -  Completion of all qualifying diagnostic and functional tests and agrees to comply with
             study follow-up schedule

        Exclusion Criteria:

          -  Patients with significant organic mitral valve pathology (e.g. myxomatous
             degeneration, mitral valve prolapse or flail leaflets)

          -  Myocardial infarction or any percutaneous cardiovascular intervention, cardiovascular
             surgery, or carotid surgery within 30 days

          -  Prior surgical, transcatheter, or percutaneous mitral valve intervention

          -  Untreated clinically significant coronary artery disease (CAD) requiring
             revascularization

          -  Hemodynamic instability: Hypotension (systolic pressure &lt;90 millimeter Mercury (mmHg))
             or requirement for inotropic support or mechanical hemodynamic support

          -  Any planned cardiac surgery or interventions within the next 6 months (including right
             heart procedures)

          -  NYHA class IVb (i.e., non-ambulatory) or American College of Cardiology (ACC)/American
             Heart Association (AHA) Stage D heart failure

          -  Fixed pulmonary artery systolic pressure &gt;70 mmHg

          -  Severe tricuspid regurgitation (per American Society of Echocardiography (ASE)
             guidelines and graded by the Echo Core Lab)

          -  Modified Rankin Scale ≥ 4 disability

          -  Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or
             any other structural heart disease causing heart failure other than dilated
             cardiomyopathy of either ischemic or non-ischemic etiology

          -  Mitral valve area less than 4.0 centimeter2 (cm2)

          -  Anatomical pathology/constraints preventing appropriate access/implant of the GDS
             AccuCinch System (e.g., femoral arteries will not support an 18 French (Fr) system)

          -  Renal insufficiency (i.e., estimated glomerular filtration rate (eGFR) of &lt;30
             milliliters/minute/meter (ml/min/1.73m2); Stage 4 or 5 chronic kidney disease (CKD))

          -  Moderate or severe aortic valve stenosis or regurgitation or aortic valve prosthesis

          -  Fluoroscopic or echocardiographic evidence of severe aortic arch calcification, mobile
             aortic atheroma, intracardiac mass, thrombus or vegetation

          -  Active bacterial endocarditis

          -  History of stroke within the prior 3 months

          -  Subjects in whom anticoagulation or anti-platelet therapy is contraindicated

          -  Known allergy to nitinol, polyester, or polyethylene

          -  Any prior true anaphylactic reaction to contrast agents; defined as known
             anaphylactoid or other non-anaphylactic allergic reactions to contrast agents that
             cannot be adequately pre-medicated prior to the index procedure.

          -  Life expectancy &lt; 1 year due to non-cardiac conditions

          -  Currently participating in another interventional investigational study

          -  Implant or revision of any rhythm management device (cardiac resynchronization therapy
             (CRT) or cardiac resynchronization therapy device (CRT-D)) or implantable cardioverter
             defibrillator within the prior month

          -  Absence of CRT with class I indication criteria for biventricular pacing (left bundle
             branch block pattern and Q-wave/R-wave/S-wave (QRS) duration ≥150 milliseconds (ms))

          -  Subjects on high dose steroids or immunosuppressant therapy

          -  Female subjects who are pregnant, of child bearing potential without a documented
             birth control method, or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Zapien, MS, CCRA</last_name>
    <role>Study Director</role>
    <affiliation>Ancora Heart, Inc. (formerly Guided Delivery Systems Inc.)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Zapien, MS, CCRA</last_name>
    <phone>408-727-1105</phone>
    <phone_ext>204</phone_ext>
    <email>mzapien@ancoraheart.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Marie Webb, RN, BSN</last_name>
      <phone>502-587-4106</phone>
      <email>anne.webb@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Kendra Grubb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Flaherty, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Slaughter, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Foundation Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Olson, RN, BSN,</last_name>
      <phone>612-863-7601</phone>
      <email>sara.olson@allina.com</email>
    </contact>
    <investigator>
      <last_name>Paul Sorajja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barnes-Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Striler, RN, MSN, CCRC</last_name>
      <phone>314-747-4452</phone>
      <email>kstriler@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>John Lasala, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nebraska Heart Institute / Nebraska Heart Hospital</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corey Godfrey, MSPE, CCRC, CEP</last_name>
      <phone>402-328-3930</phone>
      <email>cgodfrey@neheart.com</email>
    </contact>
    <investigator>
      <last_name>Hosakote Nagaraj, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Canino, RN, BS, RCIS</last_name>
      <phone>551-996-5595</phone>
      <email>Peter.Canino@hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>Carlos Ruiz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Privitera, MPH</last_name>
      <phone>212-342-3488</phone>
      <email>Lp2183@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Susheel Kodali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PinnacleHealth Cardiovascular Institute</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Regina Holister, RN</last_name>
      <email>rhollister@PINNACLEHEALTH.org</email>
    </contact>
    <investigator>
      <last_name>Hemal Gada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mubashir Mumtaz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Health Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dena Jefferson, RN, BSN, CCRC</last_name>
      <phone>717-531-5967</phone>
      <email>djefferson1@pennstatehealth.psu.edu</email>
    </contact>
    <investigator>
      <last_name>Pradeep Yadav, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine St. Luke's Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aline Barzilla, CCRC</last_name>
      <phone>832-355-3710</phone>
      <email>barzilla@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Guilherme Silva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meredith Allen</last_name>
      <phone>801-507-4769</phone>
      <email>Meredith.Allen@imail.org</email>
    </contact>
    <investigator>
      <last_name>Brian Whisenant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington Medicine</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fatemeh Ranjbaran, RN, BSN, CCRP</last_name>
      <phone>206-221-9154</phone>
      <email>FRanjbaran@cardiology.washington.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Reisman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Creighton Don, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2016</study_first_submitted>
  <study_first_submitted_qc>June 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2016</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

